M. Galsky

Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer.

Enfortumab vedotin (EV) + pembrolizumab (P; EV + P) is the preferred first-line standard-of-care treatment for metastatic urothelial carcinoma (mUC), yet predictive biomarkers remain lacking. We retrospectively investigated whether tumor NECTIN4 RNA expression and tumor mutational burden (TMB) are associated with outco...

The evolving role of perioperative systemic therapy in bladder cancer.

Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors

Abstract Background Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera Genome, a whole-genome sequencing (WGS)-based ctDNA assay, in a diverse pan-...